Security key
98937L105
Zenas BioPharma, Inc. - Common Stock, par value $0.0001 per share (ZBIO)
CUSIP: 98937L105
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 32,489,801
- Total 13F value
- $256,715,238
- Share change
- +771,275
- SEC-reported price per share
- $7.90
- Number of holders
- 67
- Value change
- +$5,759,402
- Number of buys
- 25
- Number of sells
- 30
- Shares outstanding
- 66,232,735
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
67
Top holders
10
ZBIO full security history
Ownership snapshot
Full 13F holder table
Zenas BioPharma, Inc. SEC filings
Zenas BioPharma, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of ZBIO - Zenas BioPharma, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
SR ONE CAPITAL MANAGEMENT...
Disclosed value leader
Enavate Sciences GP, LLC
Comparable rows
15/15
Latest evidence
31 Dec 2024
13F
3/4/5
Lead comparable stake: 7.4%
Showing 1-6 of 15 holder rows.
Quick read
SR ONE CAPITAL MANAGEMENT, LP leads the comparable SEC ownership view at 7.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens SR ONE CAPITAL MANAGEMENT, LP's linked filing trail.
Comparable ownership
Top 5
SR ONE CAPITAL MANAGEMENT, LP
7.4%
Enavate Sciences GP, LLC
5.7%
NEA Management Company, LLC
3.9%
Fairmount Funds Management LLC
2.9%
NVP Associates, LLC
2.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LP |
13F
Company
|
7.4%
|
$40,225,504
4,911,539 shares
|
— | 31 Dec 2024 |
| Enavate Sciences GP, LLC |
3/4/5
13F
10%+ Owner · Company
|
5.7%
from 13F
|
$63,943,103
3,761,359 shares
|
— | 16 Sep 2024 |
| NEA Management Company, LLC |
13F
Company
|
3.9%
|
$21,408,234
2,613,948 shares
|
— | 31 Dec 2024 |
| Fairmount Funds Management LLC |
13F
Company
|
2.9%
|
$15,502,081
1,892,806 shares
|
— | 31 Dec 2024 |
| NVP Associates, LLC |
13F
Company
|
2.8%
|
$15,057,168
1,838,482 shares
|
— | 31 Dec 2024 |
| FMR LLC |
13F
Company
|
2.7%
|
$14,592,246
1,781,715 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
67
Shares
32,489,801
Rows available
67
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
67
Q1 2025 holders
67
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|